MapLight Therapeutics (MPLT) Net Cash Flow (2024 - 2025)
MapLight Therapeutics recorded quarterly Net Cash Flow of -$17.4 million in Q4 2025, down 259.63% quarter-over-quarter from $10.9 million in Q4 2024, and down 259.63% year-over-year from $10.9 million in Q4 2024.
MapLight Therapeutics' Net Cash Flow history runs 2 years deep, the most recent figure standing at -$17.4 million for Q4 2025.
- In Q4 2025, Net Cash Flow fell 259.63% year-over-year to -$17.4 million; the TTM figure through Dec 2025 stood at -$6.5 million (changed N/A YoY), while the FY2025 annual figure was $8.5 million, up 120.4% from the prior year.
- Net Cash Flow came in at -$17.4 million for Q4 2025 at MapLight Therapeutics, down from $10.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $10.9 million in Q4 2024 to a low of -$17.4 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 60.68 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | -17.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.42 Mn |
| Dec 31, 2025 | -17.42 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Dec 31, 2024 | 10.91 Mn |